Literature DB >> 33405051

Dynamic biomarkers indicate the immunological benefits provided by Ganoderma spore powder in post-operative breast and lung cancer patients.

Y Deng1, J Ma2, D Tang3, Q Zhang4.   

Abstract

BACKGROUND: T lymphocyte are a strong indicator of treatment immune response. This study was aimed to determine the utility of T lymphocyte subsets, cytokines and inflammatory biomarkers in predicting the immunological benefits of Ganoderma spore powder (G. lucidum) in post-operative patients with breast and lung cancer.
METHODS: We prospectively evaluated 120 breast and lung cancer patients with or without G. lucidum. T lymphocyte subsets with relative cytokines were detected using flow cytometry and PCR and assessed by Spearman correlation analysis. The relationships between albumin-to-globulin ratio (AGR) and neutrophil-to-lymphocyte ratio (NLR) with G. lucidum treatment and prognosis were analyzed using Kaplan-Meier and Cox regression methods.
RESULTS: The prevalence of CD3 + CD4 + , CD3 + HLADR- types was higher in G. lucidum group compared to control, whilst CD4 + CD25 + Treg, CD3 + HLADR + cell types was lower. IL-12 levels were significantly higher during the treatment period which negatively impacted levels of IL-10. Other immunosuppressive factors such as COX2 and TGF-β1 had lower prevalence in treated patients. Correlation analysis showed a positive relationship between IL-10 and CD28. IL-2 was positively related to TGF-β1, whilst it was negatively related to CD3. Kaplan-Meier analysis suggested that low AGR/high NLR was related to poor progression free survival (PFS) and overall survival (OS). A combination of high AGR and low NLR may predicted treatment benefits associated with PFS and OS.
CONCLUSIONS: Our findings show that T lymphocyte subsets combined with relevant cytokines and AGR/NLR inflammatory predictors may help to identify patients most likely to benefit from the immunological enhancements from G. lucidum treatment.

Entities:  

Keywords:  Albumin-to-globulin ratio; Breast and lung cancer; Cytokines; Ganoderma spore powder; Neutrophil–to-lymphocyte ratio; T cell subsets

Mesh:

Substances:

Year:  2021        PMID: 33405051     DOI: 10.1007/s12094-020-02547-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  4 in total

1.  Cytokine production suppression by culture supernatant of B16F10 cells and amelioration by Ganoderma lucidum polysaccharides in activated lymphocytes.

Authors:  Li-Xin Sun; Wei-Dong Li; Zhi-Bin Lin; Xin-Suo Duan; En-Hong Xing; Miao-Miao Jiang; Ning Yang; Hai-Hua Qi; Yu Sun; Min Li; Yan-Dong Niu; Jie Lu
Journal:  Cell Tissue Res       Date:  2015-01-15       Impact factor: 5.249

2.  Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?

Authors:  Imperia Nuzzolese; Filippo Montemurro
Journal:  Lancet Oncol       Date:  2020-01       Impact factor: 41.316

3.  An abnormal elevation of serum CA72-4 by ganoderma lucidum spore powder.

Authors:  Yan Liang; Mingjun He; Xiaoxia Fan; Weimin Ye; Zaixing Yang; Renqian Zhong
Journal:  Ann Clin Lab Sci       Date:  2013       Impact factor: 1.256

4.  Spore Powder of Ganoderma lucidum Improves Cancer-Related Fatigue in Breast Cancer Patients Undergoing Endocrine Therapy: A Pilot Clinical Trial.

Authors:  Hong Zhao; Qingyuan Zhang; Ling Zhao; Xu Huang; Jincai Wang; Xinmei Kang
Journal:  Evid Based Complement Alternat Med       Date:  2011-12-10       Impact factor: 2.629

  4 in total
  2 in total

Review 1.  How Should the Worldwide Knowledge of Traditional Cancer Healing Be Integrated with Herbs and Mushrooms into Modern Molecular Pharmacology?

Authors:  Yulia Kirdeeva; Olga Fedorova; Alexandra Daks; Nikolai Barlev; Oleg Shuvalov
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-14

Review 2.  Current Advancements in Antitumor Properties and Mechanisms of Medicinal Components in Edible Mushrooms.

Authors:  Jing Xu; Rui Shen; Zhuoya Jiao; Weidong Chen; Daiyin Peng; Lei Wang; Nianjun Yu; Can Peng; Biao Cai; Hang Song; Fengyuan Chen; Bin Liu
Journal:  Nutrients       Date:  2022-06-24       Impact factor: 6.706

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.